YAP1 and cholangiocarcinoma: Given that Sox9 LKO specifically abrogates the Akt-YAP1 CCA region, similar to pharmacologic DNMT1 inhibition, we posited an association between SOX9 and DNMT1 in CCA fate commitment in our cHCC-CCA models.